CA3043327C - Ambroxol formulations for the treatment of ocular surface diseases and related methods - Google Patents
Ambroxol formulations for the treatment of ocular surface diseases and related methods Download PDFInfo
- Publication number
- CA3043327C CA3043327C CA3043327A CA3043327A CA3043327C CA 3043327 C CA3043327 C CA 3043327C CA 3043327 A CA3043327 A CA 3043327A CA 3043327 A CA3043327 A CA 3043327A CA 3043327 C CA3043327 C CA 3043327C
- Authority
- CA
- Canada
- Prior art keywords
- ambroxol
- formulation
- formulations
- salt form
- ocular surface
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000009472 formulation Methods 0.000 title claims abstract description 55
- 239000000203 mixture Substances 0.000 title claims abstract description 55
- JBDGDEWWOUBZPM-XYPYZODXSA-N ambroxol Chemical compound NC1=C(Br)C=C(Br)C=C1CN[C@@H]1CC[C@@H](O)CC1 JBDGDEWWOUBZPM-XYPYZODXSA-N 0.000 title claims abstract description 40
- 229960005174 ambroxol Drugs 0.000 title claims abstract description 37
- 238000000034 method Methods 0.000 title abstract description 8
- 208000023715 Ocular surface disease Diseases 0.000 title abstract description 5
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims abstract description 25
- 229920000249 biocompatible polymer Polymers 0.000 claims abstract description 8
- 208000024891 symptom Diseases 0.000 claims description 10
- 150000003839 salts Chemical group 0.000 claims description 6
- YUWPMEXLKGOSBF-GACAOOTBSA-N Anecortave acetate Chemical compound O=C1CC[C@]2(C)C3=CC[C@]4(C)[C@](C(=O)COC(=O)C)(O)CC[C@H]4[C@@H]3CCC2=C1 YUWPMEXLKGOSBF-GACAOOTBSA-N 0.000 claims description 4
- 229960001232 anecortave Drugs 0.000 claims description 4
- 229920001610 polycaprolactone Polymers 0.000 claims description 4
- 239000004632 polycaprolactone Substances 0.000 claims description 4
- 108010010803 Gelatin Proteins 0.000 claims description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- 229920000159 gelatin Polymers 0.000 claims description 3
- 239000008273 gelatin Substances 0.000 claims description 3
- 235000019322 gelatine Nutrition 0.000 claims description 3
- 235000011852 gelatine desserts Nutrition 0.000 claims description 3
- 102000008186 Collagen Human genes 0.000 claims description 2
- 108010035532 Collagen Proteins 0.000 claims description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 2
- 239000007975 buffered saline Substances 0.000 claims description 2
- 229920001436 collagen Polymers 0.000 claims description 2
- 239000000017 hydrogel Substances 0.000 claims description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 2
- 229940044192 2-hydroxyethyl methacrylate Drugs 0.000 claims 1
- HFNCOTSLOKKPHU-UHFFFAOYSA-N cyclohexanol;hydrochloride Chemical compound Cl.OC1CCCCC1 HFNCOTSLOKKPHU-UHFFFAOYSA-N 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 238000011200 topical administration Methods 0.000 claims 1
- 239000000126 substance Chemical class 0.000 abstract description 10
- 238000013265 extended release Methods 0.000 abstract description 7
- QNVKOSLOVOTXKF-UHFFFAOYSA-N 4-[(2-amino-3,5-dibromophenyl)methylamino]cyclohexan-1-ol;hydron;chloride Chemical compound Cl.NC1=C(Br)C=C(Br)C=C1CNC1CCC(O)CC1 QNVKOSLOVOTXKF-UHFFFAOYSA-N 0.000 abstract description 2
- 229960000985 ambroxol hydrochloride Drugs 0.000 abstract description 2
- 210000001508 eye Anatomy 0.000 description 15
- 239000000654 additive Substances 0.000 description 6
- 210000000795 conjunctiva Anatomy 0.000 description 5
- 230000000699 topical effect Effects 0.000 description 5
- 239000003981 vehicle Substances 0.000 description 5
- 206010013774 Dry eye Diseases 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000003974 emollient agent Substances 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 239000002674 ointment Substances 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 102000004392 Aquaporin 5 Human genes 0.000 description 3
- 108090000976 Aquaporin 5 Proteins 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 239000006196 drop Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000003889 eye drop Substances 0.000 description 3
- 229940012356 eye drops Drugs 0.000 description 3
- 230000013632 homeostatic process Effects 0.000 description 3
- 239000003002 pH adjusting agent Substances 0.000 description 3
- -1 salt ambroxol hydrochloride Chemical class 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 241000894007 species Species 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 102000010637 Aquaporins Human genes 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 206010034960 Photophobia Diseases 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 210000004087 cornea Anatomy 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000004438 eyesight Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 230000007803 itching Effects 0.000 description 2
- 208000013469 light sensitivity Diseases 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 239000004530 micro-emulsion Substances 0.000 description 2
- 210000003097 mucus Anatomy 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- 229920002818 (Hydroxyethyl)methacrylate Polymers 0.000 description 1
- FZWBNHMXJMCXLU-UHFFFAOYSA-N 2,3,4,5-tetrahydroxy-6-[3,4,5-trihydroxy-6-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxyhexanal Chemical compound OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OCC(O)C(O)C(O)C(O)C=O)O1 FZWBNHMXJMCXLU-UHFFFAOYSA-N 0.000 description 1
- 102000004363 Aquaporin 3 Human genes 0.000 description 1
- 108090000991 Aquaporin 3 Proteins 0.000 description 1
- 108010063290 Aquaporins Proteins 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000009319 Keratoconjunctivitis Sicca Diseases 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 208000022873 Ocular disease Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 210000001552 airway epithelial cell Anatomy 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 150000007514 bases Chemical class 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 229940119743 dextran 70 Drugs 0.000 description 1
- 239000007938 effervescent tablet Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229940041682 inhalant solution Drugs 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 208000018769 loss of vision Diseases 0.000 description 1
- 231100000864 loss of vision Toxicity 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 210000004175 meibomian gland Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000003232 mucoadhesive effect Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229940068984 polyvinyl alcohol Drugs 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002243 precursor Chemical class 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000036412 respiratory physiology Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000004489 tear production Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Inorganic Chemistry (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662421822P | 2016-11-14 | 2016-11-14 | |
| US62/421,822 | 2016-11-14 | ||
| US201762463717P | 2017-02-26 | 2017-02-26 | |
| US62/463,717 | 2017-02-26 | ||
| PCT/US2017/061108 WO2018089797A1 (en) | 2016-11-14 | 2017-11-10 | Formulations for the treatment of ocular surface diseases and related methods |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA3043327A1 CA3043327A1 (en) | 2018-05-17 |
| CA3043327C true CA3043327C (en) | 2020-08-11 |
Family
ID=62107036
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3043327A Active CA3043327C (en) | 2016-11-14 | 2017-11-10 | Ambroxol formulations for the treatment of ocular surface diseases and related methods |
Country Status (9)
| Country | Link |
|---|---|
| US (5) | US10265280B2 (enExample) |
| EP (1) | EP3538083B1 (enExample) |
| JP (1) | JP6871400B2 (enExample) |
| KR (1) | KR102116303B1 (enExample) |
| CN (2) | CN109982692A (enExample) |
| AU (1) | AU2017357755B2 (enExample) |
| CA (1) | CA3043327C (enExample) |
| ES (1) | ES2988280T3 (enExample) |
| WO (1) | WO2018089797A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108969511A (zh) * | 2018-07-12 | 2018-12-11 | 图桑医疗科技（深圳）有限公司 | 溴已新及其衍生物在治疗和预防眼表疾病上的应用 |
| US11326176B2 (en) | 2019-11-22 | 2022-05-10 | Mozza Foods, Inc. | Recombinant micelle and method of in vivo assembly |
| US12359212B2 (en) | 2019-11-22 | 2025-07-15 | Mozza Foods, Inc. | Recombinant micelle and method of in vivo assembly |
| CN112915090A (zh) * | 2019-12-07 | 2021-06-08 | 王明武 | 用于治疗眼表疾病的一类化合物及其相关制剂和应用方法 |
| AU2023277608A1 (en) * | 2022-05-21 | 2024-11-28 | Neuvision Development Llc | Topical ocular administration of ambroxol for ocular pain |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU574360B2 (en) | 1983-05-13 | 1988-07-07 | Reichert, D. | Antisnoring agent |
| DE3610997A1 (de) | 1986-04-02 | 1987-10-15 | Krewel Werke Gmbh | Ambroxol-nasenspray |
| DE3731528A1 (de) * | 1987-09-18 | 1989-04-13 | Krewel Werke Gmbh | Verwendung von trans-4- ((2-amino-3,5-dibrom-benzyl)-amino) -cyclohexanol zur lokalen behandlung von erkrankungen des auges |
| JPH08509725A (ja) | 1993-04-30 | 1996-10-15 | ザ、プロクター、エンド、ギャンブル、カンパニー | コートされた医薬組成物 |
| US5458879A (en) | 1994-03-03 | 1995-10-17 | The Procter & Gamble Company | Oral vehicle compositions |
| IT1303671B1 (it) | 1998-07-28 | 2001-02-23 | Nicox Sa | Sali dell'acido nitrico con farmaci attivi nel trattamento dipatologie del sistema respiratorio |
| AU770803B2 (en) | 1998-12-23 | 2004-03-04 | Idea Ag | Improved formulation for topical non-invasive application in vivo |
| DE19933148A1 (de) | 1999-07-20 | 2001-01-25 | Boehringer Ingelheim Int | Ambroxolhaltige Lutschtablette |
| US7179849B2 (en) | 1999-12-15 | 2007-02-20 | C. R. Bard, Inc. | Antimicrobial compositions containing colloids of oligodynamic metals |
| CA2373171A1 (en) | 2000-03-07 | 2001-09-13 | Teijin Limited | Stretch plaster |
| US20030216423A1 (en) | 2000-05-24 | 2003-11-20 | Sergio Ulloa | Stable liquid and solid formulations |
| ITRM20010438A1 (it) * | 2001-07-23 | 2003-01-23 | Farmigea Spa | Preparato oftalmico a base di n-acetilcisteina per il trattamento della sindrome dell'occhio secco. |
| DE10140320A1 (de) | 2001-08-16 | 2003-03-06 | Udo Zirfas | Potenzfördernder und vitaltonisierender Wirkstoff |
| DE10203104A1 (de) | 2002-01-25 | 2003-08-07 | Boehringer Ingelheim Pharma | Ambroxol für die Behandlung chronischer Schmerzen |
| US20030171391A1 (en) | 2002-01-25 | 2003-09-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Ambroxol for the treatment of chronic pain |
| DE10208313A1 (de) | 2002-02-27 | 2003-09-11 | Boehringer Ingelheim Pharma | Ambroxol für die Behandlung von schmerzhaften Zuständen im Mund und Rachenraum |
| US20030166732A1 (en) | 2002-02-27 | 2003-09-04 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Ambroxol for the treatment of painful conditions in the mouth and pharyngeal cavity |
| JP2004175749A (ja) * | 2002-11-28 | 2004-06-24 | Senju Pharmaceut Co Ltd | ドライアイおよびドライアイを伴う疾病の治療剤 |
| DE10332487A1 (de) | 2003-07-16 | 2005-02-10 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Ambroxol für die Behandlung von chronisch nozizeptiven Schmerzen |
| DE10332486A1 (de) | 2003-07-16 | 2005-02-10 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Ambroxol für die Behandlung akuter Schmerzen |
| DE10332473A1 (de) | 2003-07-16 | 2005-02-03 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Ambroxol für die Behandlung von Epilepsie |
| AU2003904192A0 (en) * | 2003-08-11 | 2003-08-21 | Adelaide Research and Innovaiton Pty Ltd | Method for inhibiting bacterial colonisation |
| KR20050036166A (ko) * | 2003-10-15 | 2005-04-20 | 베링거 잉겔하임 파르마 게엠베하 운트 코 카게 | 인두내 염증 치료용 암브록솔 |
| US9016221B2 (en) | 2004-02-17 | 2015-04-28 | University Of Florida Research Foundation, Inc. | Surface topographies for non-toxic bioadhesion control |
| DE102004021992A1 (de) | 2004-05-03 | 2005-11-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Topische Zubereitung enthaltend Ambroxol |
| US20070014833A1 (en) * | 2005-03-30 | 2007-01-18 | Sirtris Pharmaceuticals, Inc. | Treatment of eye disorders with sirtuin modulators |
| CA2609549A1 (en) * | 2005-05-25 | 2006-11-30 | Sirtris Pharmaceuticals, Inc. | Treatment of eye disorders with sirtuin modulators |
| JP5337405B2 (ja) | 2007-09-17 | 2013-11-06 | ザ・ホスピタル・フォー・シック・チルドレン | ゴーシェ病の治療方法 |
| GB0801876D0 (en) | 2008-02-01 | 2008-03-12 | Vectura Group Plc | Suspension formulations |
| US8784870B2 (en) | 2008-07-21 | 2014-07-22 | Otonomy, Inc. | Controlled release compositions for modulating free-radical induced damage and methods of use thereof |
| GB0921481D0 (en) | 2009-12-08 | 2010-01-20 | Vectura Ltd | Process and product |
| WO2011106702A2 (en) | 2010-02-25 | 2011-09-01 | The Johns Hopkins University | Sustained delivery of therapeutic agents to an eye compartment |
| EP2793872B1 (en) | 2011-12-22 | 2021-03-10 | Centogene IP GmbH | Combination of a compound having the ability to rearrange a lysosomal enzyme and ambroxol and/or a derivative of ambroxol |
| CN102670607A (zh) | 2012-05-28 | 2012-09-19 | 海南卫康制药(潜山)有限公司 | 复方盐酸氨溴索组合物及其制备方法 |
| US20140235554A1 (en) * | 2013-02-12 | 2014-08-21 | Brian Lawrence | Ophthalmic formulation derived from silk protein |
| HU231191B1 (hu) | 2013-04-15 | 2021-08-30 | Szegedi Tudományegyetem | Izotóp tartalmú morfin molekulák |
| AU2014309251B2 (en) | 2013-08-23 | 2018-05-24 | Parion Sciences, Inc. | Dithiol mucolytic agents |
-
2017
- 2017-11-10 CN CN201780070126.8A patent/CN109982692A/zh active Pending
- 2017-11-10 US US15/809,659 patent/US10265280B2/en active Active
- 2017-11-10 CN CN202210992714.XA patent/CN115607531A/zh active Pending
- 2017-11-10 CA CA3043327A patent/CA3043327C/en active Active
- 2017-11-10 JP JP2019546769A patent/JP6871400B2/ja active Active
- 2017-11-10 ES ES17868628T patent/ES2988280T3/es active Active
- 2017-11-10 KR KR1020197016988A patent/KR102116303B1/ko active Active
- 2017-11-10 AU AU2017357755A patent/AU2017357755B2/en active Active
- 2017-11-10 EP EP17868628.3A patent/EP3538083B1/en active Active
- 2017-11-10 WO PCT/US2017/061108 patent/WO2018089797A1/en not_active Ceased
-
2019
- 2019-03-19 US US16/358,517 patent/US20190209496A1/en not_active Abandoned
-
2020
- 2020-11-02 US US17/087,504 patent/US20210046022A1/en not_active Abandoned
-
2022
- 2022-07-28 US US17/875,871 patent/US20220378723A1/en not_active Abandoned
-
2024
- 2024-05-15 US US18/664,847 patent/US20240374540A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN115607531A (zh) | 2023-01-17 |
| US20210046022A1 (en) | 2021-02-18 |
| JP6871400B2 (ja) | 2021-05-12 |
| KR102116303B1 (ko) | 2020-05-29 |
| AU2017357755B2 (en) | 2019-06-13 |
| WO2018089797A1 (en) | 2018-05-17 |
| EP3538083B1 (en) | 2024-07-10 |
| US20220378723A1 (en) | 2022-12-01 |
| US20180133173A1 (en) | 2018-05-17 |
| CA3043327A1 (en) | 2018-05-17 |
| AU2017357755A1 (en) | 2019-05-30 |
| US20190209496A1 (en) | 2019-07-11 |
| CN109982692A (zh) | 2019-07-05 |
| US10265280B2 (en) | 2019-04-23 |
| EP3538083A4 (en) | 2020-05-27 |
| ES2988280T3 (es) | 2024-11-19 |
| JP2019534335A (ja) | 2019-11-28 |
| US20240374540A1 (en) | 2024-11-14 |
| KR20190085038A (ko) | 2019-07-17 |
| EP3538083A1 (en) | 2019-09-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2877184B1 (en) | Compositions and treatment for eye diseases and disorders | |
| US20240374540A1 (en) | Formulations for the treatment of ocular surface diseases and related methods | |
| CN112915090A (zh) | 用于治疗眼表疾病的一类化合物及其相关制剂和应用方法 | |
| TWI632913B (zh) | 用於眼部疾病或異常之組合物及其治療方法 | |
| Halder et al. | Efficacy and safety of bimatoprost 0.01% formulated in tight junction modulation technology compared to marketed benzalkonium chloride preserved bimatoprost 0.01% ophthalmic solution in healthy beagle dogs | |
| US20210052582A1 (en) | Methods of use and pharmaceutical compositions of a selective syk inhibitor | |
| CN105214092B (zh) | 重组人白细胞介素-1受体拮抗剂及其组合物及药物用途 | |
| KR20240130701A (ko) | 알라닐-글루타민 및 알라닐-글루타민을 포함하는 안과용 조성물의 새로운 용도 | |
| HK1210968B (en) | Compositions and treatment for eye diseases and disorders |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20190508 |